Develops investigational antibodies and antibody combinations for people with inflammatory bowel disease and rheumatic diseases.
10-K for FY2025, filed Feb 19, 2026
Immedica licensed pegzilarginase commercialization rights in Europe and specified Middle Eastern countries; Spyre later sold Immedica global rights to the product.
10-K for FY2025, filed Feb 19, 2026
10-Q for Q3 FY2026, filed Nov 3, 2026
−$96.1MView ↗
8-K, filed Jun 1, 2026
On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreement (the "Amendment"), amending the…View ↗
From enzymes to antibodies
The business moved from developing human enzyme therapies for rare metabolic diseases to developing long-acting antibodies and antibody combinations for inflammatory bowel and rheumatic diseases.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Feb 19, 2026We are a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases. Our…View ↗
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody…View ↗
Competes with AbbVie, Johnson & Johnson, Lilly, Takeda, Pfizer, Bristol Myers Squibb, Merck, Roche, Roivant, Sanofi, Teva, Innovent, Gilead, Palisade Bio, Sorriso, Earendil, Simcere, Boehringer Ingelheim, Xencor, and UCB
10-K for FY2025, filed Feb 19, 2026We expect to face intense competition from other biopharmaceutical companies that are developing agents for the treatment of inflammatory…View ↗
Loading...